|View printer-friendly version|
|June 16, 2008 3:11 p.m.|
|Teva's AZILECT® 1 mg Tablets Meet End Points in ADAGIO Phase III Trial|
AZILECT® Market Potential Dramatically Increases, as the Drug Could Become the First Disease Modifying Treatment for Parkinson's Disease
Jerusalem, Israel, June 16, 2008 - Teva Pharmaceutical Industries Ltd. (NASDAQ: TEVA) announced today the successful completion of ADAGIO, the phase III study designed to demonstrate that AZILECT® 1 mg tablets can slow down the progression of Parkinson's disease. In the trial, the currently marketed AZILECT® 1 mg tablets met all three primary end points, as well as the secondary and additional end points, all with statistical significance. The study also confirmed the safety and tolerability of AZILECT®.